BLR&D Research Career Scientist Award Application

BLR

• 批准号: 10293563
• 负责人: Chandrasekar Bysani
• 金额: --
• 依托单位: HARRY S. TRUMAN MEMORIAL VA HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-10-01 至 2022-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10293563
• 关键词: Affect; Aldosterone; Angiotensin II; Atherosclerosis; Award; Binding; Bioinformatics; Biopsy; Cardiac; Cardiac Myocytes; Cardiovascular Diseases; Cell Death; Centers for Disease Control and Prevention (U.S.); Characteristics; Chronic Disease; Collaborations; Collagen; Colorado; Complement Factor H; Critical Pathways; Deposition; Development; Diabetes Mellitus; Disease Progression; Endothelial Cells; Epidermal Growth Factor Receptor; Etiology; Family member; Fibrillar Collagen; Fibroblasts; Florida; Functional disorder; Funding; GPI Membrane Anchors; Gene Deletion; Genes; Genetic Transcription; Goals; Healthcare; Healthcare Systems; Heart; Heart Diseases; Heart Hypertrophy; Heart Injuries; Heart failure; Human; Hypertension; Hypertrophy; IL6ST gene; In Vitro; Infarction; Inflammation; Inflammatory; Interleukin-1; Interleukin-1 Receptors; Interleukin-1 beta; Interleukin-17; Interleukin-18; Interleukin-2; Interleukins; Intervention Studies; Isoproterenol; Knock-in Mouse; Knock-out; Lead; MAP Kinase Gene; MAPK8 gene; Matrix Metalloproteinase Inhibitor; Matrix Metalloproteinases; Mediating; Mediator of activation protein; Membrane; Messenger RNA; Microbubbles; Mission; Modeling; Molecular; Morbidity - disease rate; Mutate; Myocardial; Myocardial Ischemia; Myocardial dysfunction; Nodal; Obesity; Oxidative Stress; Pathogenesis; Pathologic; Pathology; Patient-Focused Outcomes; Patients; Persons; Pharmacology; Pilot Projects; Play; Population; Problem Solving; Progressive Disease; Proteins; Publications; RNA; RNA-Binding Proteins; Recombinant Interleukins; Reperfusion Injury; Reporting; Research; Research Personnel; Ribonucleoproteins; Role; Scientist; Services; Signal Transduction; Signal Transduction Pathway; Smoking; Survivors; System; TLR4 gene; TNF receptor-associated factor 3; Therapeutic; Time; Tissues; Transcription Factor AP-1; Transgenic Mice; United States National Center for Health Statistics; Universities; Ventricular Remodeling; Veterans; antagonist; aortic valve replacement; career; cell type; chemokine; comorbidity; coronary fibrosis; cysteine rich protein; cytokine; efficacy testing; gain of function; gene therapy; glycoprotein 130; improved; improved functioning; in vivo; interleukin-1 receptor accessory protein; interleukin-18 receptor; ischemic injury; loss of function; migration; military veteran; mortality; mouse model; myocardial injury; neutralizing antibody; new therapeutic target; overexpression; p38 Mitogen Activated Protein Kinase; pressure; receptor; sex; siRNA delivery; stem; therapeutic target; tissue injury; transcription factor; ubiquitin ligase; ultrasound

ABSTRACT Nearly 63 million people (20% of the US population) are eligible for VA benefits and services because they are veterans, family members or survivors of veterans. Cardiovascular diseases (CVD) contribute to significant morbidity and mortality of the military veterans and civilians (CDC/National Center for Health Statistics). I have been associated with VA and non-VA funded clinician-scientists and basic researchers for the past 20 years. I am also a VA funded investigator. The overall focus of my research as a VA funded scientist is to investigate the causal role of inflammation, inflammatory cytokines and chemokines, and NF-κB activation in CVD. Since inflammation is a critical component in the pathogenesis of CVD, and CVD are the major contributing factors for morbidity and mortality within both military veteran and civilian populations of both sexes, my studies are highly relevant to the VA mission. Furthermore, hypertension, diabetes, obesity and smoking predispose veterans and civilians alike to CVD, my ongoing studies are timely and critical in further understanding the pathophysiology of these chronic diseases. Using the most promising research strategies and problem-solving approaches, my goal is to identify newer therapeutic targets in CVD. TRAF3 Interacting Protein 2 (TRAF3IP2) is a cytoplasmic adapter molecule and an upstream regulator of at least three major signal transduction pathways that are known to play a pathological role in ischemic cardiac diseases. TRAF3IP2 activates IKK/NF-κB, JNK/AP-1 and p38 MAPK, and induces the expression of multiple cytokines and chemokines with negative myocardial inotropic effects. It also regulates the expression of collagens and MMPs. TRAF3IP2 is a critical intermediate in IL-17 signaling, another proinflammatory cytokine involved in ischemic cardiac disease. Our preliminary results show that TRAF3IP2 also plays a role in IL-18 signaling. In fact, we found that TRAF3IP2 binds the TIR (The Toll/Il-1 Receptor)-domain containing IL-18 receptor via binding motifs that appear to be different from those responsible for TRAF3IP2/IL-17R binding. Bioinformatics revealed that TRAF3IP2 could also associate with IL-1RacP (Interleukin 1 Receptor Accessory Protein), an IL- 1β receptor. We previously reported that TRAF3IP2 also plays a role in LPS/Toll-like receptor 4-mediated cardiomyocyte contractile dysfunction, suggesting that targeting TRAF3IP2 could blunt IL-17, IL-18, IL-1 and LPS signaling, all of which contribute causally to various cardiac pathologies, including cardiac ischemic injury. Utilizing both in vivo (genetic and interventional) and in vitro (cardiomyocytes and cardiac fibroblasts) models, my ongoing studies are examining the relationship between TRAF3IP2, inflammation and heart failure (HF) of ischemic/non-ischemic origin in vivo and the underlying molecular mechanisms in vitro. My long-term goal is to develop therapeutic strategies to inhibit TRAF3IP2 expression. Recently, we targeted TRAF3IP2 by UTMD (ultrasound-targeted microbubble destruction)-mediated delivery of AS-ODN into LV, and demonstrated significant reduction in cardiac TRAF3IP2 expression, myocardial injury (infarct size), adverse remodeling and HF development. In addition, my ongoing studies are focused on unraveling the roles of the RNA binding protein Larp6 (stimulates collagen I and III expression) and the membrane-anchored protein RECK (inhibits multiple MMPs, ADAMs, EGFR, uPA and gp130) in adverse cardiac remodeling and HF development. !!

抽象的 近 6300 万人（占美国人口的 20%）有资格享受 VA 福利和服务，因为 他们是退伍军人、退伍军人的家庭成员或幸存者，他们对心血管疾病（CVD）做出了贡献。 退伍军人和平民的显着发病率和死亡率（疾病预防控制中心/国家卫生中心 我一直与 VA 和非 VA 资助的临床医生科学家和基础研究人员合作。 过去 20 年，我也是一名 VA 资助的研究员。 科学家将研究炎症、炎性细胞因子和趋化因子以及 NF-κB 的因果作用 由于炎症是 CVD 发病机制的关键组成部分，而 CVD 是 CVD 的关键因素。 两国退伍军人和平民发病率和死亡率的主要影响因素 此外，我的研究与 VA 的使命高度相关，包括高血压、糖尿病、肥胖症和性别。 吸烟会使退伍军人和平民容易患心血管疾病，我正在进行的研究对于进一步的研究是及时且关键的 使用最有前途的研究策略了解这些慢性疾病的病理生理学。 和解决问题的方法，我的目标是确定 CVD 中更新的治疗靶点。 蛋白 2 (TRAF3IP2) 是一种细胞质接头分子，是至少三个主要蛋白的上游调节因子 已知在缺血性心脏病中发挥病理作用的信号转导途径。 TRAF3IP2 激活 IKK/NF-κB、JNK/AP-1 和 p38 MAPK，并诱导多种细胞因子的表达 和具有负向心肌肌力作用的趋化因子，它还调节胶原蛋白的表达和 MMPs 是 IL-17 信号传导的关键中间体，IL-17 是另一种参与炎症的细胞因子。 我们的初步结果表明 TRAF3IP2 也在 IL-18 信号传导中发挥作用。 事实上，我们发现TRAF3IP2通过含有IL-18受体的TIR（Toll/Il-1受体）结构域结合 结合基序似乎与负责 TRAF3IP2/IL-17R 结合的基序不同。 研究表明 TRAF3IP2 还可以与 IL-1RacP（白细胞介素 1 受体辅助蛋白）相关联，IL-1RacP 是一种 IL-1RacP（白细胞介素 1 受体辅助蛋白）。 我们之前报道过 TRAF3IP2 在 LPS/Toll 样受体 4 介导中也发挥作用。 心肌细胞收缩功能障碍，表明靶向 TRAF3IP2 可以减弱 IL-17、IL-18、IL-1 和 LPS 信号转导，所有这些信号都会导致各种心脏病，包括心脏缺血性损伤。 利用体内（遗传和介入）和体外（心肌细胞和心脏成纤维细胞）模型， 我正在进行的研究正在检查 TRAF3IP2、炎症和心力衰竭 (HF) 之间的关系 我的长期目标是体内缺血/非缺血起源和体外潜在的分子机制。 开发抑制 TRAF3IP2 表达的治疗策略 最近，我们通过 UTMD 靶向 TRAF3IP2。 （超声靶向微泡破坏）介导的 AS-ODN 递送至 LV，并证明 心脏 TRAF3IP2 表达、心肌损伤（梗塞面积）、不良重构和 此外，我正在进行的研究重点是阐明 RNA 结合的作用。 Larp6 蛋白（刺激 I 型和 III 型胶原蛋白表达）和膜锚定蛋白 RECK（抑制 多种 MMP、ADAM、EGFR、uPA 和 gp130）在不良心脏重塑和心力衰竭发展中的作用。 !!